Clinical Trial Update: Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults With or Without EBV Infection [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of an Epstein-Barr virus gp350-Ferritin nanoparticle vaccine in healthy adults with or without prior EBV infec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Infectious Mononucleosis

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: EBV, Epstein-Barr Virus Infection | Phase 1 | Status: ACTIVE_NOT_RECRUITING